119 related articles for article (PubMed ID: 35673748)
41. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
Duléry R; Nibourel O; Gauthier J; Elsermans V; Behal H; Coiteux V; Magro L; Renneville A; Marceau A; Boyer T; Quesnel B; Preudhomme C; Duhamel A; Yakoub-Agha I
Bone Marrow Transplant; 2017 Apr; 52(4):539-543. PubMed ID: 28067876
[TBL] [Abstract][Full Text] [Related]
42. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
43. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic Hematopoietic Stem Cell Transplantation Improved Survival for Adult Core Binding Factor Acute Myelogenous Leukemia Patients with Intermediate- and Adverse-Risk Genetics in the 2017 European LeukemiaNet.
Wang T; Chen S; Chen J; Liu T; Zhang T; Qiu H; Sun A; Chen S; Wu D; Xu Y
Transplant Cell Ther; 2021 Feb; 27(2):173.e1-173.e9. PubMed ID: 33830030
[TBL] [Abstract][Full Text] [Related]
45. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
46. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
47. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
[TBL] [Abstract][Full Text] [Related]
48. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
[TBL] [Abstract][Full Text] [Related]
49. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
50. Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
Guolo F; Di Grazia C; Minetto P; Raiola AM; Clavio M; Miglino M; Tedone E; Contini P; Mangerini R; Kunkl A; Colombo N; Pugliese G; Carminati E; Marcolin R; Passannante M; Bagnasco S; Galaverna F; Lamparelli T; Ballerini F; Cagnetta A; Cea M; Gobbi M; Bacigalupo A; Lemoli RM; Angelucci E
Eur J Haematol; 2021 Nov; 107(5):573-582. PubMed ID: 34297437
[TBL] [Abstract][Full Text] [Related]
51. Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
Wang T; Zhou B; Zhang J; Zhang X; Liu T; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Lymphoma; 2021 Apr; 62(4):995-998. PubMed ID: 33191833
[TBL] [Abstract][Full Text] [Related]
52. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
53. [Outcomes of adults with Ph-negative B-cell acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of minimal residual disease].
Ding Z; Han M; Chen S; Ma Q; Wei J; Pang A; Huang Y; Zhang X; Liang C; Liu X; Yao J; Li G; Cao Y; Feng S; Jiang E
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):587-92. PubMed ID: 26304084
[TBL] [Abstract][Full Text] [Related]
54. [Effects of Pre-Transplant CONUT and Post-Transplant MRD on Prognosis of Patients with Multiple Myeloma after Auto-HSCT].
Xiong YY; Zhou Q; Chen L; Yu W; Zhang HB; Chen JB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):146-154. PubMed ID: 38387913
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared With Chemotherapy as Postremission Treatment of Children With Intermediate-risk Acute Myeloid Leukemia in First Complete Remission.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Suo P; Zhang LP; Huang XJ
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e126-e136. PubMed ID: 33060049
[TBL] [Abstract][Full Text] [Related]
56. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
57. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
58. [Effect of NCCN (2015) risk stratification on prognosis of patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Wang H; Liu HX; Wang T; Tong CR; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):44-49. PubMed ID: 28219225
[No Abstract] [Full Text] [Related]
59. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
60. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.
Venditti A; Buccisano F; Del Poeta G; Maurillo L; Tamburini A; Cox C; Battaglia A; Catalano G; Del Moro B; Cudillo L; Postorino M; Masi M; Amadori S
Blood; 2000 Dec; 96(12):3948-52. PubMed ID: 11090082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
